Business Description
Verrica Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US92511W1080
Description
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.53 | |||||
| Equity-to-Asset | 0.24 | |||||
| Debt-to-Equity | 2.3 | |||||
| Debt-to-EBITDA | -0.73 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -2.64 | |||||
| Beneish M-Score | 6.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.5 | |||||
| 3-Year EPS without NRI Growth Rate | 5.9 | |||||
| 3-Year FCF Growth Rate | 12.2 | |||||
| 3-Year Book Growth Rate | -28.9 | |||||
| Future 3-5Y Total Revenue Growth Rate | 73.73 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 76.72 | |||||
| 9-Day RSI | 77.82 | |||||
| 14-Day RSI | 73.13 | |||||
| 6-1 Month Momentum % | 31.95 | |||||
| 12-1 Month Momentum % | -21.06 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.55 | |||||
| Quick Ratio | 4.49 | |||||
| Cash Ratio | 4.09 | |||||
| Days Inventory | 318.27 | |||||
| Days Sales Outstanding | 203.78 | |||||
| Days Payable | 736.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.6 | |||||
| Shareholder Yield % | -10.24 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 85.44 | |||||
| Operating Margin % | -1233.82 | |||||
| Net Margin % | -1307.48 | |||||
| FCF Margin % | -758.77 | |||||
| ROE % | -150.66 | |||||
| ROA % | -94.54 | |||||
| ROIC % | -713.33 | |||||
| ROC (Joel Greenblatt) % | -1196.89 | |||||
| ROCE % | -100.35 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 63.6 | |||||
| PB Ratio | 15.15 | |||||
| Price-to-Tangible-Book | 15.09 | |||||
| EV-to-EBIT | -4.37 | |||||
| EV-to-EBITDA | -4.43 | |||||
| EV-to-Revenue | 53.75 | |||||
| EV-to-Forward-Revenue | 9.86 | |||||
| EV-to-FCF | -7.07 | |||||
| Price-to-Net-Current-Asset-Value | 19.09 | |||||
| Price-to-Net-Cash | 38.18 | |||||
| Earnings Yield (Greenblatt) % | -22.88 | |||||
| FCF Yield % | -13 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Verrica Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 4.759 | ||
| EPS (TTM) (€) | -1.363 | ||
| Beta | 3.28 | ||
| Volatility % | 97.18 | ||
| 14-Day RSI | 73.13 | ||
| 14-Day ATR (€) | 0.14822 | ||
| 20-Day SMA (€) | 5.51775 | ||
| 12-1 Month Momentum % | -21.06 | ||
| 52-Week Range (€) | 2.6 - 6.6 | ||
| Shares Outstanding (Mil) | 42.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Verrica Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Verrica Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Verrica Pharmaceuticals Inc Frequently Asked Questions
What is Verrica Pharmaceuticals Inc(FRA:1NE)'s stock price today?
The current price of FRA:1NE is €6.49. The 52 week high of FRA:1NE is €6.60 and 52 week low is €2.60.
When is next earnings date of Verrica Pharmaceuticals Inc(FRA:1NE)?
The next earnings date of Verrica Pharmaceuticals Inc(FRA:1NE) is 2024-05-09 Est..
Does Verrica Pharmaceuticals Inc(FRA:1NE) pay dividends? If so, how much?
Verrica Pharmaceuticals Inc(FRA:1NE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers